An Act amending the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, further providing for drug overdose medication.

PRINTER'S NO. 2835
THE GENERAL ASSEMBLY OF PENNSYLVANIA
HOUSE BILL
No. 2181
Session of
2026
INTRODUCED BY PIELLI, MUNROE, McNEILL, HILL-EVANS, SANCHEZ,
BRENNAN, D. WILLIAMS, O'MARA, GREEN, HANBIDGE, DALEY, CEPEDA-
FREYTIZ AND BOROWSKI, JANUARY 30, 2026
REFERRED TO COMMITTEE ON HEALTH, JANUARY 30, 2026
AN ACT
Amending the act of April 14, 1972 (P.L.233, No.64), entitled
"An act relating to the manufacture, sale and possession of
controlled substances, other drugs, devices and cosmetics;
conferring powers on the courts and the secretary and
Department of Health, and a newly created Pennsylvania Drug,
Device and Cosmetic Board; establishing schedules of
controlled substances; providing penalties; requiring
registration of persons engaged in the drug trade and for the
revocation or suspension of certain licenses and
registrations; and repealing an act," further providing for
drug overdose medication.
The General Assembly of the Commonwealth of Pennsylvania
hereby enacts as follows:
Section 1. Section 13.8(h) of the act of April 14, 1972
(P.L.233, No.64), known as The Controlled Substance, Drug,
Device and Cosmetic Act, is amended to read:
Section 13.8. Drug Overdose Medication.--* * *
(h) As used in this section, the term "opioid antagonist"
means a drug or device approved by the Federal Food, Drug, and
Cosmetic Act (52 Stat. 1040, 21 U.S.C. § 301 et seq.) for
emergency reversal of known or suspected opioid overdose,
including naloxone hydrochloride, nalmefene hydrochloride or
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
other similarly acting drugs approved by the United States Food
and Drug Administration for the treatment of an opioid overdose.
Section 2. This act shall take effect in 60 days.
20260HB2181PN2835 - 2 -
1
2
3